Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells

Annals of Allergy, Asthma and Immunology

Volumn 95, Issue 5, 2005, Pages 443-451

  Huang, Yu Ching ^b   Leyko, Bartlomiej ^b   Frieri, Marianne ^a  

^a NASSAU UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIGEN; BUDESONIDE; CARBON DIOXIDE; CORTICOSTEROID; CYTOKINE; EPITHELIAL GROWTH FACTOR; GROWTH FACTOR; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; MESSENGER RNA; MONOCLONAL ANTIBODY; NITRIC OXIDE; OMALIZUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHUS MUCOSA; CELL STIMULATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; TEMPERATURE;

EID: 28044431859     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61170-2     Document Type: Article

References (34)

1. Leung DYM. Molecular basis of allergic diseases. Mol Genet Metab. 1998;63:157-167.
2. Babu KS, Arshad SH, Holgate ST. Anti-IgE treatment: an update. Allergy. 2001;56:1121-1128.
3. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184-190.
4. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254-261.
5. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108:E36.
6. Johansson SGO, Haahtela T, O'Byrne PM. Omalizumab and the immune system: an overview of preclinical and clinical data. Ann Allergy Asthma Immunol. 2002;89:132-138.
7. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol. 2003;131:46-52.
8. Djukanovic R, Wilson S, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170:583-593.
9. John M, Oltmanns U, Binder C, et al. Inhibition of chemokine production from human airway smooth muscle cells by fluticasone, budesonide and beclomethasone. Pulm Pharmacol Ther. 2004;17:41-47.
10. Ward C, Pais M, Bish R, et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax. 2002;57:309-316.
11. Vignola AM, Chanez P, Chiappara G, et al. Transforming growth factor-β expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med. 1997;156(pt 1):591-599.
12. Campbell AM, Vachier I, Chanez P, et al. Expression of the high-affinity receptor for IgE on bronchial epithelial cells of asthmatics. Am J Respir Cell Mol Biol. 1998;19:92-97.
13. Saini SS, MacGlashan DW Jr, Sterbinsky SA, et al. Down-regulation of human basophil IgE and FcεRIα surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol. 1999;162:5624-5630.
14. Capetandes A, Home NS, Frieri M. Dermatophagoides extract-treated confluent type II epithelial cells (A549) secrete soluble factors that alter human lung mesenchymal cell growth. Ann Allergy Asthma Immunol. 2005;95:381-388.
15. MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438-1445.
16. Casale TB, Costa JJ, Galli SJ. TNF-α is important in human lung allergic reactions. Am J Respir Cell Mol Biol. 1996;15:35-44.
17. Borish LC, Steinke JW. Cytokines and chemokines. J Allergy Clin Immunol. 2003;111(suppl):S460-S475.
18. Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST. Airway remodeling in asthma: new insights. J Allergy Clin Immunol. 2003:111:215-225.
19. Frieri M. Asthma concepts in the new millennium: update in asthma pathophysiology. Allergy Asthma Proc. 2005;26:83-88.
20. Richter A, Puddicombe SM, Lordan JL, et al. The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma. Am J Respir Cell Mol Biol. 2001;25:385-391.
21. Silkoff PE, Robbins RA, Gaston B, et al. Endogenous nitric oxide in allergic airway disease. J Allergy Clin Immunol. 2000;105:438-448.
22. Silkoff PE, Romero FA, Gupta N, et al. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics. 2004;113:e308-e312.
23. Warke TJ, Fitch PS, Brown V, et al. Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax. 2002;57:383-387.
24. Bates C, Silkoff PE. Exhaled nitric oxide in asthma: from bench to bedside. J Allergy Clin Immunol. 2003;111:256-262.
25. Chapman JT, Choi AMK. Exhaled monoxides as a pulmonary function test: use of exhaled nitric oxide and carbon monoxide. Clin Chest Med. 2001;22:817-836.
26. Strunk RC, Szefler SJ, Phillips BR. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol. 2003;112:883-892.
27. Frieri M, May B. Anti-inflammatory effect of tecastemizole on nasal epithelial cell production of IL-8, IL-Iβ and nitric oxide [abstract]. J Allergy Clin Immunol. 2003;111:592a.
28. Hacena M, Moll B, Goodwin C, et al. Assessment of IL-8, TNFα, TGFβ, and nitric oxide release and expression from antigen and growth factor stimulated pulmonary epithelial cells with budesonide [abstract]. J Allergy Clin Immunol. 2002;109:38a.
29. Sade K, Kivity S. Nitric oxide in asthma. Isr Med Assoc J. 2002;4:196-199.
30. Frieri M. Nitric oxide in allergic rhinitis and asthma. Allergy Asthma Proc. 1998;19:349-351.
31. Taylor-Robinson AW, Liew FY, Severn A. Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells. Eur J Immunol. 1994;24:980-984.
32. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997;155:1828-1834.
33. D'Amato G, Liccardi G, Noschese P, et al. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases. Curr Drug Targets Inflamm Allergy. 2004;3:227-229.
34. Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcεRI expression. J Allergy Clin Immunol. 2003;112:1147-1154.